论文部分内容阅读
目的应用动态血压监测评价替米沙坦-氢氯噻嗪治疗轻、中度原发性高血压的长效降压作用。方法开放性临床试验设计,安慰剂导入期2wk筛选轻、中度原发性高血压病人24例,接受替米沙坦治疗2wk(80mg,po,qd),换成替米沙坦-氢氯噻嗪(80mg/12.5mg,po,qd),持续6wk。在安慰剂导入期末和活性药物治疗期末分别行24h动态血压监测。结果经过8wk治疗后,所有病人24h平均收缩压(SBP)和舒张压(DBP)的谷峰比值分别为0.78和0.61,24hSBP和DBP的平滑指数分别为1.8±s0.8和1.6±0.6,24hSBP和DBP分别较安慰剂导入期末降低(27±11)和(16±6)mmHg,日间与夜间SBP及DBP降低幅度相近,不良反应为轻到中度。结论替米沙坦-氢氯噻嗪治疗轻、中度高血压降压效果持久且平稳。
Objective To evaluate the long-term antihypertensive effect of telmisartan-hydrochlorothiazide in the treatment of mild to moderate essential hypertension by ambulatory blood pressure monitoring. Methods Open clinical trial design, placebo induction period of 2wk screening mild to moderate essential hypertension in patients with 24 cases, receiving telmisartan treatment 2wk (80mg, po, qd), replaced by telmisartan - hydrochlorothiazide 80 mg / 12.5 mg, po, qd) for 6 weeks. Ambulatory blood pressure monitoring was performed at the end of the placebo and at the end of the active drug treatment. Results After 8wk treatment, the peak-to-peak mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) of all patients were 0.78 and 0.61, the smoothing index of 24 hSBP and DBP were 1.8 ± s 0.8 and 1.6 ± 0.6, 24 hSBP And DBP decreased (27 ± 11) and (16 ± 6) mmHg, respectively, compared with placebo at the end of the study. The reductions in SBP and DBP during daytime and nighttime were similar with mild to moderate adverse reactions. Conclusion Telmisartan - hydrochlorothiazide treatment of mild to moderate hypertension has long-lasting and stable antihypertensive effect.